X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13) 13
humans (12) 12
multiple myeloma (12) 12
hematology, oncology and palliative medicine (10) 10
multiple myeloma - drug therapy (10) 10
oncology (9) 9
bortezomib (8) 8
aged (7) 7
female (7) 7
male (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
treatment outcome (6) 6
care and treatment (5) 5
dexamethasone (5) 5
hematology (5) 5
middle aged (5) 5
multiple myeloma - mortality (5) 5
transplants & implants (5) 5
adult (4) 4
chemotherapy (4) 4
dexamethasone - administration & dosage (4) 4
multiple myeloma - pathology (4) 4
neoplasm recurrence, local - drug therapy (4) 4
patients (4) 4
product development (4) 4
prognosis (4) 4
survival (4) 4
thalidomide - administration & dosage (4) 4
toxicity (4) 4
abridged index medicus (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
clinical trials (3) 3
diagnosis (3) 3
disease-free survival (3) 3
drug administration schedule (3) 3
drug dosages (3) 3
europe (3) 3
lenalidomide (3) 3
lenalidomide plus dexamethasone (3) 3
medicine, general & internal (3) 3
motivation (3) 3
neoplasm recurrence, local - mortality (3) 3
neoplasm staging (3) 3
plasma (3) 3
prednisone (3) 3
proteins (3) 3
randomization (3) 3
risk factors (3) 3
safety (3) 3
stem-cell transplantation (3) 3
steroids (3) 3
studies (3) 3
survival analysis (3) 3
thalidomide (3) 3
thalidomide - analogs & derivatives (3) 3
therapy (3) 3
transplantation (3) 3
age factors (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antineoplastic agents - therapeutic use (2) 2
antitumor-activity (2) 2
asia (2) 2
autografts (2) 2
bone marrow (2) 2
bone-marrow (2) 2
boronic acids - administration & dosage (2) 2
bortezomib - adverse effects (2) 2
cell survival (2) 2
congresses (2) 2
corticosteroids (2) 2
diarrhea (2) 2
diseases (2) 2
dosage and administration (2) 2
double-blind method (2) 2
drug resistance, neoplasm - drug effects (2) 2
drug therapy (2) 2
drugs (2) 2
follow-up studies (2) 2
hemic and lymphatic diseases (2) 2
infections (2) 2
intravenous administration (2) 2
kaplan-meier estimate (2) 2
lbh589 (2) 2
maintenance (2) 2
medical prognosis (2) 2
medical services (2) 2
melphalan (2) 2
melphalan - administration & dosage (2) 2
multicenter (2) 2
multiparameter flow-cytometry (2) 2
multiple myeloma - complications (2) 2
multiple myeloma - diagnosis (2) 2
multiple-myeloma (2) 2
neoplasm recurrence, local - pathology (2) 2
north america (2) 2
outcomes (2) 2
peripheral nervous system diseases - chemically induced (2) 2
peripheral neuropathy (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 11/2016, Volume 39, Issue 11, pp. 742 - 742
Journal Article
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 11, pp. e506 - e515
Summary Background Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus... 
Hematology, Oncology and Palliative Medicine | MULTICENTER | LBH589 | LENALIDOMIDE | END-POINTS | RISK | OUTCOMES | COMBINATION | HEMATOLOGY | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Dexamethasone - adverse effects | Male | Fatigue - chemically induced | Multiple Myeloma - ethnology | Bortezomib - pharmacology | Dexamethasone - pharmacology | Time Factors | Renal Insufficiency - complications | Panobinostat | Patient Dropouts - statistics & numerical data | Thrombocytopenia - chemically induced | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Dexamethasone - therapeutic use | Geography - statistics & numerical data | Indoles - adverse effects | Bortezomib - therapeutic use | Bortezomib - adverse effects | Survival Analysis | Creatinine - blood | Quality of Life | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Age Factors | Multiple Myeloma - mortality | Hydroxamic Acids - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Diarrhea - chemically induced | Neoplasm Recurrence, Local - mortality | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Multiple Myeloma - drug therapy | Chromosome Aberrations - statistics & numerical data | Chromosome Aberrations - drug effects | Adult | Female | Indoles - pharmacology | Steroids - therapeutic use | Hydroxamic Acids - pharmacology | Double-Blind Method | Blood Cell Count - statistics & numerical data | Multiple Myeloma - complications | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Treatment Outcome | Asthenia - chemically induced | Hydroxamic Acids - pharmacokinetics | Asian Continental Ancestry Group - ethnology | Disease-Free Survival | Activities of Daily Living - classification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Indoles - pharmacokinetics | Aged | Neoplasm Staging | Bortezomib - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | Immunologic Factors - therapeutic use
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1055 - 1066
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 12, pp. 1157 - 1165
Summary The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide,... 
Hematology, Oncology and Palliative Medicine | APOPTOSIS | IN-VITRO | ONCOLOGY | BONE-MARROW | ACID COMBINATION THERAPY | CELL-PROLIFERATION | KAPPA-B PATHWAY | PROTEASOME INHIBITOR | ANTITUMOR-ACTIVITY | HEMATOLOGIC MALIGNANCIES | ARSENIC TRIOXIDE | Apoptosis - drug effects | Humans | Heat-Shock Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Depsipeptides - pharmacology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Multiple Myeloma - drug therapy | Receptors, Cell Surface - drug effects | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Multiple Myeloma - physiopathology | NF-kappa B - antagonists & inhibitors | Protein Kinases - drug effects | Antibodies, Monoclonal - pharmacology | Arsenicals - pharmacology | Enzyme Inhibitors - pharmacology | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - drug effects | Oxides - pharmacology | Signal Transduction - drug effects | Farnesyl-Diphosphate Farnesyltransferase - antagonists & inhibitors | Cysteine Proteinase Inhibitors - pharmacology | Histone Deacetylase Inhibitors | TOR Serine-Threonine Kinases | Cell Cycle - drug effects | Oligopeptides - pharmacology | Antigens, Surface - drug effects | DNA Methylation - drug effects | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Drugs | Medical research | Multiple myeloma | Clinical trials | Medicine, Experimental | Drug therapy | Drug approval
Journal Article
by Dimopoulos, Meletios A and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Agnieszka and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Rowlings, Phillip and Taylor, Kerry and Spencer, Andrew and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Hajek, Roman and Maisnar, Vladimir and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Moreau, Philippe and Blau, Igor and Goldschmidt, Hartmut and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Weisel, Katja and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Dimopoulos, Athanasios and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and ... and TOURMALINE-MM3 study group and TOURMALINE-MM3 Study Grp
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Journal Article
Journal Article